TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00123305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Microplasmin
Description: 1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Microplasmin
Description: 1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
Study: NCT03836365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative counseling office visit
Description: All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have an in person preoperative counseling office visit.
Study: NCT04015193

Intervention type: PROCEDURE
Intervention: Single-port thoracoscopic sympathicotomy (patient care)
Description: Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure

Intervention type: PROCEDURE
Intervention: Single-port thoracoscopic sympathicotomy (patient care)
Description: Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure

Intervention type: PROCEDURE
Intervention: Single-port thoracoscopic sympathicotomy (patient care)
Description: Single-port thoracoscopic sympathicotomy will be performed as part of patient care, data will be collected of patients undergoing this procedure
Study: NCT03836365

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Preoperative counseling phone call
Description: All patients undergo a preoperative counseling session prior to surgery. Participants in this arm will have a preoperative counseling phone call.
Study: NCT01560520

Intervention type: BEHAVIORAL
Intervention: Physical activity
Description: Observation only
Study: NCT02709122

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThoraQuik atraumatic set for pneumothorax decompression
Description: pneumothorax decompression in case it is found in accordance with the actually recommendations

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ThoraQuik atraumatic set for pneumothorax decompression
Description: pneumothorax decompression in case it is found in accordance with the actually recommendations
Study: NCT01899976

Intervention type: DEVICE
Group type: OTHER
Intervention: X-Suit NIR Covered Biliary Stent
Study: NCT03608696

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Description: buprenorphine 0.075 mg/ml solution
Study: NCT01002131

Intervention type: DEVICE
Intervention: CBCT
Description: Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
Study: NCT03804931

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation
Description: 200 mL of prepared fecal microbiota suspension from healthy donors' fresh feces was injected into the intestine

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Infusion of Saline
Description: Infusion of Saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
Description: Mesalazine and/or Prednisone

Intervention type: DRUG
Group type: OTHER
Intervention: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
Description: Mesalazine and/or Prednisone

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: 5-Aminosalicylic acid(5-ASA) and/or Prednisone
Description: Mesalazine and/or Prednisone
Study: NCT02688816

Intervention type: DEVICE
Intervention: Xpert HPV
Description: Point-of-care HPV DNA PCR test
Study: NCT01242527

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 4 capsules (1g) daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 2 capsules (1g) + 2 placebo daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 3 capsules (1g) + 1 placebo daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omefas
Description: 4 capsules (1g)daily for 12 weeks
Study: NCT02256462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (\> 40kg 160/80/40 mg every 2 weeks or \< 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
Study: NCT01990053

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beating the Blues
Description: The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
Study: NCT04345848

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Two different doses of anticoagulation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: Two different doses of anticoagulation
Study: NCT03719066

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: killed whole cell oral cholera vaccine
Description: two week interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: killed whole cell oral cholera vaccine
Description: two week interval

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: killed whole cell oral cholera vaccine
Description: two week interval
Study: NCT03832569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab 200 mg IV every 3 weeks over 30 minutes.
Study: NCT00124501

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback-assisted relaxation training
Description: 10 sessions BART

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Biofeedback-assisted relaxation training
Description: 10 sessions BART
Study: NCT02688816

Intervention type: DEVICE
Intervention: OncoE6
Description: Point-of-care E6 oncoprotein test
Study: NCT03132116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gentamicin
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.~As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28).
Study: NCT01546194

Intervention type: OTHER
Intervention: Phone call explaining the research project
Description: A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial

Intervention type: OTHER
Intervention: Phone call explaining the research project
Description: A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
Study: NCT01185678

Intervention type: DRUG
Intervention: Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)
Description: One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
Study: NCT02079623

Intervention type: PROCEDURE
Intervention: Electroporation/ Nano knife treatment

Intervention type: DEVICE
Intervention: NanoKnife
Study: NCT02611895

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HIV DNA
Description: Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
Study: NCT04433767

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transdermal Nicotine patch
Description: Participants will begin a 12- week open label trial of transdermal nicotine patch during the day and remove it at night (16 hours). Dose titration starting at 3.5 mg patch/daily to maximum of 21mg patch/daily.~After week 12 , dose will be slowly tapered over 3 weeks.
Study: NCT01682291

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Life-style modifications
Description: Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplements
Description: combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
Study: NCT01469689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Google Adwords
Description: The investigators will display Google Adwords advertising the investigators' website offering online help for depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Google Adwords
Description: The investigators will display Google Adwords advertising the investigators' website offering online help for depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local organisation websites
Description: The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Local organisation websites
Description: The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
Study: NCT05146791

Intervention type: PROCEDURE
Intervention: Inlay Bristow
Description: A modified Bristow procedure

Intervention type: PROCEDURE
Intervention: Bristow
Description: Traditional Bristow procedure
Study: NCT02057055

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soap 300000027003

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Soap 300000029240
Study: NCT01389219

Intervention type: OTHER
Group type: OTHER
Intervention: Intervention
Description: A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;~1. Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron \& vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.~2. Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.~3. Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.~5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections.
Study: NCT04258696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode laser
Description: using Ultrapak Knitted retraction cord as a gingival retraction method . using Wiser Cordless Dental Diode Laser from Doctor Smile Dental Laser By LAMBDA SpA Italy as a gingival retraction method.• The tip of diode laser, will be angled toward the soft tissue and away from the prepared tooth, will be passed along the gingival sulcus to remove the sulcular epithelium. Constant and steady short brushing strokes gently removed the lining of the sulcus in order to achieve a full 360-degree trough. The tip will be constantly cleaned with a gauze sponge wetted with hydrogen peroxide to remove debris and to eliminate potential bacterial contamination. sufﬁcient epithelium will be removed to place the impression material and visualize the ﬁnishing line. The tissue will be kept moist with water during the procedure then impression will be taken

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ultrapak Knitted retraction cord
Description: using Ultrapak Knitted retraction cord as a gingival retraction method retraction cord will be applied for 8-10 mins then an impression will be taken , poured to obtain a cast and the die sectioned
Study: NCT02977546

Intervention type: DEVICE
Intervention: Noninvasive pulse contour analysis
Description: For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)

Intervention type: DEVICE
Intervention: Pulmonary artery catheterization
Description: As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
Study: NCT04175834

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cetrizine
Description: prophylaxis

Intervention type: DRUG
Group type: OTHER
Intervention: diphenhydramine
Description: prophylaxis
Study: NCT06458361

Intervention type: PROCEDURE
Intervention: Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis
Description: Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods

Intervention type: PROCEDURE
Intervention: Type of bowel resection, surgical complexity score, intraoperative blood loss, perioperative erythrocyte transfusion, type of anastomosis
Description: Basic information about ovarian cancer patients and factors associated with preoperative, intraoperative and postoperative periods
Study: NCT01450358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Antibiotic regimen
Description: The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
Study: NCT00375089

Intervention type: OTHER
Intervention: Group 1
Description: Individuals with Prader-Willi syndrome. Monitoring every 6 months.

Intervention type: OTHER
Intervention: Group 2
Description: Individuals with Early-onset Morbid Obesity.
Study: NCT03841864

Intervention type: OTHER
Group type: OTHER
Intervention: IV placement using ultrasound guidance vs traditional method
Description: Ultrasound guided IV placement

Intervention type: OTHER
Group type: OTHER
Intervention: IV placement using ultrasound guidance vs traditional method
Description: Ultrasound guided IV placement
Study: NCT01028209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] PBR06
Description: Subjects will be injected with 5mCi, not to exceed \>10% of 5mCI, of \[18F\]PBR06, followed by PET imaging.
Study: NCT03087266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FM-SRP
Description: Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
Study: NCT03841864

Intervention type: OTHER
Group type: OTHER
Intervention: IV placement using ultrasound guidance vs traditional method
Description: Ultrasound guided IV placement
Study: NCT03087266

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Q-SRP
Description: Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
Study: NCT01056744

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention with stent implantation
Description: Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous coronary intervention with stent implantation
Description: Percutaneous coronary intervention with implantation of either:~- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),~or:~- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)
Study: NCT00214136

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: prostate radiation to 70Gy; nodal radiation to 56Gy
Study: NCT02435693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PHARMACEUTICAL CARE programe
Description: The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.

Intervention type: OTHER
Group type: OTHER
Intervention: Without PHARMACEUTICAL CARE programe
Study: NCT02655913

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vitamin C
Description: Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Modulated Electro-Hyperthermia (mEHT)
Description: MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
Study: NCT03617016

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Domperidone
Description: Participants will receive domperidone tablets orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive matching placebo to domperidone tablets orally.
Study: NCT04331600

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine phosphate
Description: Oral chloroquine phosphate for 14 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telemedicine
Description: Telemedical supervision for 42 days

Intervention type: OTHER
Group type: OTHER
Intervention: Telemedicine
Description: Telemedical supervision for 42 days
Study: NCT04287920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acomprosate
Description: Acamprosate will be administered orally and will be dosed at 333 mg three times a day, if tolerated it will be increased to 666 mg three times a day. Acamprosate will be administered for a total of 3 months
Study: NCT02620319

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SX-ELLA Stent DV Tracheal (DV Stent)
Description: The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
Study: NCT01286688

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terbinafine Hydrochloride Tablets, 250 mg
Description: Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
Study: NCT03232905

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: PF-06651600 will be administered as tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be administered as tablet
Study: NCT00943384

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chronOS Strip
Description: chronOS strip combined with bone marrow aspirate plus local bone